Topic:

Emerging Markets

Latest Headlines

Latest Headlines

German Merck tracking drugs in Africa with texts

A startup company has taken aim at drug counterfeiting in developing countries with a technology that relies on cell phones and what it refers to on its website as "crowd-sourced pharmacovigilance."

Pharma rides a wave of targeted M&A deals

The reasons behind the dealmaking aren't new: Established markets are slowing down as emerging markets speed up, sending companies shopping in the developing world.

Australian researchers prepare for bionic eye trial

Melbourne researchers with the Monash Vision Group, who are on track to have a direct-to-brain bionic eye implant ready for human trials next year, are ready to test its first full system prototype this month.

Covidien sees strong quarter on device sales, emerging markets growth

Earnings season continues, and this morning, Covidien ($COV) released positive results in a quarter that witnessed a 7% rise in device sales.

Watson formally unveils its $5.6B-plus deal for Actavis

Watson Pharmaceuticals has agreed to buy its Swiss-based rival Actavis. The price was about what the gossips expected: a total of $5.9 billion.

Sandoz transferring cGMP expertise to Africa's Cinpharm

Sandoz sees lots of potential but is taking an indirect route to build a production footprint in sub-Saharan Africa.

J&J's Gorsky will target device deals for emerging markets

Expect Johnson & Johnson ($JNJ) to start spending some of its $14 billion in cash on medical device deals to help expand its presence in emerging markets once Alex Gorsky becomes CEO.

Chiltern finds clinical opportunities in Taiwan

Chiltern, an international contract research organization, landed a legal entity in Taiwan, enabling it to conduct clinical trial services in the island nation.

BioMérieux Q1 2012 sales soar, propelled by China, India

Sales growth surpassing 21% in the Asia-Pacific region helped produce healthy numbers for French in vitro diagnostics player bioMérieux in the company's 2012 first quarter.

EnteroMedics sees first product revenues

Last week, we profiled EnteroMedics' ($ETRM) seeming rise from the ashes. Today, it's reporting its first product revenues.